Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine
Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced